The Yin and Yang of nucleic acid-based therapy in the brain
• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gustincich, Stefano [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
18 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill - Zhou, Nan ELSEVIER, 2021, an international review journal, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:155 ; year:2017 ; pages:194-211 ; extent:18 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.pneurobio.2016.11.001 |
|---|
| Katalog-ID: |
ELV025280813 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV025280813 | ||
| 003 | DE-627 | ||
| 005 | 20230625144516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pneurobio.2016.11.001 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017009000030.pica |
| 035 | |a (DE-627)ELV025280813 | ||
| 035 | |a (ELSEVIER)S0301-0082(15)30099-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 690 |q VZ |
| 084 | |a 56.45 |2 bkl | ||
| 100 | 1 | |a Gustincich, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Yin and Yang of nucleic acid-based therapy in the brain |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 18 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. | ||
| 520 | |a • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. | ||
| 650 | 7 | |a NAT |2 Elsevier | |
| 650 | 7 | |a APP |2 Elsevier | |
| 650 | 7 | |a PR |2 Elsevier | |
| 650 | 7 | |a BBB |2 Elsevier | |
| 650 | 7 | |a IL24 |2 Elsevier | |
| 650 | 7 | |a ALS |2 Elsevier | |
| 650 | 7 | |a UBE3A |2 Elsevier | |
| 650 | 7 | |a piRNAs |2 Elsevier | |
| 650 | 7 | |a Aub |2 Elsevier | |
| 650 | 7 | |a UTR |2 Elsevier | |
| 650 | 7 | |a SYNGAP1 |2 Elsevier | |
| 650 | 7 | |a shRNA |2 Elsevier | |
| 650 | 7 | |a Foxg1 |2 Elsevier | |
| 650 | 7 | |a CCR4 |2 Elsevier | |
| 650 | 7 | |a ED |2 Elsevier | |
| 650 | 7 | |a SLC39A |2 Elsevier | |
| 650 | 7 | |a AntagoNATs |2 Elsevier | |
| 650 | 7 | |a RNAi |2 Elsevier | |
| 650 | 7 | |a AD |2 Elsevier | |
| 650 | 7 | |a Emx2 |2 Elsevier | |
| 650 | 7 | |a SINEUP |2 Elsevier | |
| 650 | 7 | |a TEs |2 Elsevier | |
| 650 | 7 | |a SMA |2 Elsevier | |
| 650 | 7 | |a iPSC |2 Elsevier | |
| 650 | 7 | |a ASOs |2 Elsevier | |
| 650 | 7 | |a RISCs |2 Elsevier | |
| 650 | 7 | |a polyA |2 Elsevier | |
| 650 | 7 | |a SINE |2 Elsevier | |
| 650 | 7 | |a eRNA |2 Elsevier | |
| 650 | 7 | |a BACE1 |2 Elsevier | |
| 650 | 7 | |a SMN |2 Elsevier | |
| 650 | 7 | |a TSS |2 Elsevier | |
| 650 | 7 | |a AAV |2 Elsevier | |
| 650 | 7 | |a FTD |2 Elsevier | |
| 650 | 7 | |a HA epitope |2 Elsevier | |
| 650 | 7 | |a Cas9 |2 Elsevier | |
| 650 | 7 | |a lincRNAs |2 Elsevier | |
| 650 | 7 | |a FXN |2 Elsevier | |
| 650 | 7 | |a RAPGEF3 |2 Elsevier | |
| 650 | 7 | |a SHANK2 |2 Elsevier | |
| 650 | 7 | |a lncRNAs |2 Elsevier | |
| 650 | 7 | |a TFs |2 Elsevier | |
| 650 | 7 | |a TGS |2 Elsevier | |
| 650 | 7 | |a BD |2 Elsevier | |
| 650 | 7 | |a miRNAs |2 Elsevier | |
| 650 | 7 | |a bPLA2G4A |2 Elsevier | |
| 650 | 7 | |a DHX9 |2 Elsevier | |
| 650 | 7 | |a S/AS |2 Elsevier | |
| 650 | 7 | |a HTT |2 Elsevier | |
| 650 | 7 | |a PSEN1 |2 Elsevier | |
| 650 | 7 | |a siRNAs |2 Elsevier | |
| 650 | 7 | |a GFP |2 Elsevier | |
| 650 | 7 | |a CSF |2 Elsevier | |
| 650 | 7 | |a LINE |2 Elsevier | |
| 650 | 7 | |a COX2 |2 Elsevier | |
| 650 | 7 | |a PABP |2 Elsevier | |
| 650 | 7 | |a RNAa |2 Elsevier | |
| 650 | 7 | |a LDLR |2 Elsevier | |
| 650 | 7 | |a wt |2 Elsevier | |
| 650 | 7 | |a GOI |2 Elsevier | |
| 650 | 7 | |a IL32 |2 Elsevier | |
| 650 | 7 | |a CRISPR |2 Elsevier | |
| 650 | 7 | |a Uchl1 |2 Elsevier | |
| 650 | 7 | |a BDNF |2 Elsevier | |
| 650 | 7 | |a VEGF |2 Elsevier | |
| 650 | 7 | |a FRDA |2 Elsevier | |
| 650 | 7 | |a IGF2 |2 Elsevier | |
| 650 | 7 | |a NMHVs |2 Elsevier | |
| 650 | 7 | |a SOD1 |2 Elsevier | |
| 650 | 7 | |a 3C |2 Elsevier | |
| 650 | 7 | |a PD |2 Elsevier | |
| 650 | 7 | |a CCPG1 |2 Elsevier | |
| 650 | 7 | |a CSDC2 |2 Elsevier | |
| 650 | 7 | |a Ago2 |2 Elsevier | |
| 650 | 7 | |a saRNA |2 Elsevier | |
| 650 | 7 | |a RIP |2 Elsevier | |
| 650 | 7 | |a HD |2 Elsevier | |
| 650 | 7 | |a RAN |2 Elsevier | |
| 700 | 1 | |a Zucchelli, Silvia |4 oth | |
| 700 | 1 | |a Mallamaci, Antonello |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Zhou, Nan ELSEVIER |t Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |d 2021 |d an international review journal |g Amsterdam [u.a.] |w (DE-627)ELV006964737 |
| 773 | 1 | 8 | |g volume:155 |g year:2017 |g pages:194-211 |g extent:18 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.pneurobio.2016.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 56.45 |j Baustoffkunde |q VZ |
| 951 | |a AR | ||
| 952 | |d 155 |j 2017 |h 194-211 |g 18 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s g sg |
|---|---|
| matchkey_str |
gustincichstefanozucchellisilviamallamac:2017----:hynnynonceccdaetea |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
56.45 |
| publishDate |
2017 |
| allfields |
10.1016/j.pneurobio.2016.11.001 doi GBVA2017009000030.pica (DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 56.45 bkl Gustincich, Stefano verfasserin aut The Yin and Yang of nucleic acid-based therapy in the brain 2017transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier Zucchelli, Silvia oth Mallamaci, Antonello oth Enthalten in Elsevier Zhou, Nan ELSEVIER Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill 2021 an international review journal Amsterdam [u.a.] (DE-627)ELV006964737 volume:155 year:2017 pages:194-211 extent:18 https://doi.org/10.1016/j.pneurobio.2016.11.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 56.45 Baustoffkunde VZ AR 155 2017 194-211 18 045F 610 |
| spelling |
10.1016/j.pneurobio.2016.11.001 doi GBVA2017009000030.pica (DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 56.45 bkl Gustincich, Stefano verfasserin aut The Yin and Yang of nucleic acid-based therapy in the brain 2017transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier Zucchelli, Silvia oth Mallamaci, Antonello oth Enthalten in Elsevier Zhou, Nan ELSEVIER Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill 2021 an international review journal Amsterdam [u.a.] (DE-627)ELV006964737 volume:155 year:2017 pages:194-211 extent:18 https://doi.org/10.1016/j.pneurobio.2016.11.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 56.45 Baustoffkunde VZ AR 155 2017 194-211 18 045F 610 |
| allfields_unstemmed |
10.1016/j.pneurobio.2016.11.001 doi GBVA2017009000030.pica (DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 56.45 bkl Gustincich, Stefano verfasserin aut The Yin and Yang of nucleic acid-based therapy in the brain 2017transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier Zucchelli, Silvia oth Mallamaci, Antonello oth Enthalten in Elsevier Zhou, Nan ELSEVIER Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill 2021 an international review journal Amsterdam [u.a.] (DE-627)ELV006964737 volume:155 year:2017 pages:194-211 extent:18 https://doi.org/10.1016/j.pneurobio.2016.11.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 56.45 Baustoffkunde VZ AR 155 2017 194-211 18 045F 610 |
| allfieldsGer |
10.1016/j.pneurobio.2016.11.001 doi GBVA2017009000030.pica (DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 56.45 bkl Gustincich, Stefano verfasserin aut The Yin and Yang of nucleic acid-based therapy in the brain 2017transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier Zucchelli, Silvia oth Mallamaci, Antonello oth Enthalten in Elsevier Zhou, Nan ELSEVIER Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill 2021 an international review journal Amsterdam [u.a.] (DE-627)ELV006964737 volume:155 year:2017 pages:194-211 extent:18 https://doi.org/10.1016/j.pneurobio.2016.11.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 56.45 Baustoffkunde VZ AR 155 2017 194-211 18 045F 610 |
| allfieldsSound |
10.1016/j.pneurobio.2016.11.001 doi GBVA2017009000030.pica (DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 56.45 bkl Gustincich, Stefano verfasserin aut The Yin and Yang of nucleic acid-based therapy in the brain 2017transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. • We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier Zucchelli, Silvia oth Mallamaci, Antonello oth Enthalten in Elsevier Zhou, Nan ELSEVIER Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill 2021 an international review journal Amsterdam [u.a.] (DE-627)ELV006964737 volume:155 year:2017 pages:194-211 extent:18 https://doi.org/10.1016/j.pneurobio.2016.11.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 56.45 Baustoffkunde VZ AR 155 2017 194-211 18 045F 610 |
| language |
English |
| source |
Enthalten in Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill Amsterdam [u.a.] volume:155 year:2017 pages:194-211 extent:18 |
| sourceStr |
Enthalten in Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill Amsterdam [u.a.] volume:155 year:2017 pages:194-211 extent:18 |
| format_phy_str_mv |
Article |
| bklname |
Baustoffkunde |
| institution |
findex.gbv.de |
| topic_facet |
NAT APP PR BBB IL24 ALS UBE3A piRNAs Aub UTR SYNGAP1 shRNA Foxg1 CCR4 ED SLC39A AntagoNATs RNAi AD Emx2 SINEUP TEs SMA iPSC ASOs RISCs polyA SINE eRNA BACE1 SMN TSS AAV FTD HA epitope Cas9 lincRNAs FXN RAPGEF3 SHANK2 lncRNAs TFs TGS BD miRNAs bPLA2G4A DHX9 S/AS HTT PSEN1 siRNAs GFP CSF LINE COX2 PABP RNAa LDLR wt GOI IL32 CRISPR Uchl1 BDNF VEGF FRDA IGF2 NMHVs SOD1 3C PD CCPG1 CSDC2 Ago2 saRNA RIP HD RAN |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |
| authorswithroles_txt_mv |
Gustincich, Stefano @@aut@@ Zucchelli, Silvia @@oth@@ Mallamaci, Antonello @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV006964737 |
| dewey-sort |
3610 |
| id |
ELV025280813 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025280813</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625144516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.pneurobio.2016.11.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017009000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025280813</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0301-0082(15)30099-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gustincich, Stefano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Yin and Yang of nucleic acid-based therapy in the brain</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BBB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL24</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ALS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">UBE3A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">piRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aub</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">UTR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SYNGAP1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">shRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Foxg1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCR4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ED</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLC39A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AntagoNATs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Emx2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINEUP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TEs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ASOs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RISCs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">polyA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">eRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BACE1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TSS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AAV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FTD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HA epitope</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cas9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">lincRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FXN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAPGEF3</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SHANK2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">lncRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TFs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bPLA2G4A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DHX9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">S/AS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HTT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSEN1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">siRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GFP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CSF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LINE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COX2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PABP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAa</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LDLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">wt</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GOI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL32</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRISPR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uchl1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BDNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FRDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IGF2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NMHVs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SOD1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">3C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCPG1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CSDC2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ago2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">saRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RIP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zucchelli, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mallamaci, Antonello</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Zhou, Nan ELSEVIER</subfield><subfield code="t">Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill</subfield><subfield code="d">2021</subfield><subfield code="d">an international review journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006964737</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:155</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:194-211</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.pneurobio.2016.11.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.45</subfield><subfield code="j">Baustoffkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">155</subfield><subfield code="j">2017</subfield><subfield code="h">194-211</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Gustincich, Stefano |
| spellingShingle |
Gustincich, Stefano ddc 610 ddc 690 bkl 56.45 Elsevier NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN The Yin and Yang of nucleic acid-based therapy in the brain |
| authorStr |
Gustincich, Stefano |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV006964737 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 690 VZ 56.45 bkl The Yin and Yang of nucleic acid-based therapy in the brain NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN Elsevier |
| topic |
ddc 610 ddc 690 bkl 56.45 Elsevier NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN |
| topic_unstemmed |
ddc 610 ddc 690 bkl 56.45 Elsevier NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN |
| topic_browse |
ddc 610 ddc 690 bkl 56.45 Elsevier NAT Elsevier APP Elsevier PR Elsevier BBB Elsevier IL24 Elsevier ALS Elsevier UBE3A Elsevier piRNAs Elsevier Aub Elsevier UTR Elsevier SYNGAP1 Elsevier shRNA Elsevier Foxg1 Elsevier CCR4 Elsevier ED Elsevier SLC39A Elsevier AntagoNATs Elsevier RNAi Elsevier AD Elsevier Emx2 Elsevier SINEUP Elsevier TEs Elsevier SMA Elsevier iPSC Elsevier ASOs Elsevier RISCs Elsevier polyA Elsevier SINE Elsevier eRNA Elsevier BACE1 Elsevier SMN Elsevier TSS Elsevier AAV Elsevier FTD Elsevier HA epitope Elsevier Cas9 Elsevier lincRNAs Elsevier FXN Elsevier RAPGEF3 Elsevier SHANK2 Elsevier lncRNAs Elsevier TFs Elsevier TGS Elsevier BD Elsevier miRNAs Elsevier bPLA2G4A Elsevier DHX9 Elsevier S/AS Elsevier HTT Elsevier PSEN1 Elsevier siRNAs Elsevier GFP Elsevier CSF Elsevier LINE Elsevier COX2 Elsevier PABP Elsevier RNAa Elsevier LDLR Elsevier wt Elsevier GOI Elsevier IL32 Elsevier CRISPR Elsevier Uchl1 Elsevier BDNF Elsevier VEGF Elsevier FRDA Elsevier IGF2 Elsevier NMHVs Elsevier SOD1 Elsevier 3C Elsevier PD Elsevier CCPG1 Elsevier CSDC2 Elsevier Ago2 Elsevier saRNA Elsevier RIP Elsevier HD Elsevier RAN |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s z sz a m am |
| hierarchy_parent_title |
Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |
| hierarchy_parent_id |
ELV006964737 |
| dewey-tens |
610 - Medicine & health 690 - Building & construction |
| hierarchy_top_title |
Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV006964737 |
| title |
The Yin and Yang of nucleic acid-based therapy in the brain |
| ctrlnum |
(DE-627)ELV025280813 (ELSEVIER)S0301-0082(15)30099-X |
| title_full |
The Yin and Yang of nucleic acid-based therapy in the brain |
| author_sort |
Gustincich, Stefano |
| journal |
Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |
| journalStr |
Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
194 |
| author_browse |
Gustincich, Stefano |
| container_volume |
155 |
| physical |
18 |
| class |
610 610 DE-600 690 VZ 56.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gustincich, Stefano |
| doi_str_mv |
10.1016/j.pneurobio.2016.11.001 |
| dewey-full |
610 690 |
| title_sort |
yin and yang of nucleic acid-based therapy in the brain |
| title_auth |
The Yin and Yang of nucleic acid-based therapy in the brain |
| abstract |
• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. |
| abstractGer |
• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. |
| abstract_unstemmed |
• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
The Yin and Yang of nucleic acid-based therapy in the brain |
| url |
https://doi.org/10.1016/j.pneurobio.2016.11.001 |
| remote_bool |
true |
| author2 |
Zucchelli, Silvia Mallamaci, Antonello |
| author2Str |
Zucchelli, Silvia Mallamaci, Antonello |
| ppnlink |
ELV006964737 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.pneurobio.2016.11.001 |
| up_date |
2024-07-06T17:08:55.898Z |
| _version_ |
1803850335807078400 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025280813</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625144516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.pneurobio.2016.11.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017009000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025280813</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0301-0082(15)30099-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gustincich, Stefano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Yin and Yang of nucleic acid-based therapy in the brain</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We introduce our current understanding on the functional output of the mammalian genome, paying special attention to long non-coding RNAs and their potential applications in molecular therapy. • We discuss the challenges for the molecular therapy in the brain and we highlight the renaissance of nucleic acid-based drugs to treat neurodegenerative diseases. We describe the potential therapeutic effects that can be obtained by inhibiting (Yin) and increasing (Yang) gene expression. • The Yin side of nucleic acid-based therapy: we summarize the current technologies and we provide examples of their applications to treat to neurodegenerative diseases in mouse models and in clinical trials. • The Yang side of nucleic acid-based therapy: we discuss the molecular basis of new classes of activatory RNA-based drugs, acting at the transcriptional (saRNAs and NMHVs) and translational (SINEUPs) levels. We provide examples of activatory RNA therapy in neurodegenerative disorders in mouse models and in clinical trials. • We conclude with our vision on the future perspectives of nucleic acid-based therapy in the brain.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BBB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL24</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ALS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">UBE3A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">piRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aub</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">UTR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SYNGAP1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">shRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Foxg1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCR4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ED</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SLC39A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AntagoNATs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Emx2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINEUP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TEs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ASOs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RISCs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">polyA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">eRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BACE1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TSS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AAV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FTD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HA epitope</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cas9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">lincRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FXN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAPGEF3</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SHANK2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">lncRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TFs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bPLA2G4A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DHX9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">S/AS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HTT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSEN1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">siRNAs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GFP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CSF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LINE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COX2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PABP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAa</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LDLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">wt</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GOI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL32</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRISPR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uchl1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BDNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FRDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IGF2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NMHVs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SOD1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">3C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCPG1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CSDC2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ago2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">saRNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RIP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zucchelli, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mallamaci, Antonello</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Zhou, Nan ELSEVIER</subfield><subfield code="t">Influences of mine water on the properties of construction and demolition waste-based cemented paste backfill</subfield><subfield code="d">2021</subfield><subfield code="d">an international review journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006964737</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:155</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:194-211</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.pneurobio.2016.11.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.45</subfield><subfield code="j">Baustoffkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">155</subfield><subfield code="j">2017</subfield><subfield code="h">194-211</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4007177 |